Trillium Therapeutics to Present at Investor and Scientific Conferences in April

TORONTO, ONTARIO--(Marketwired - March 29, 2017) - Trillium Therapeutics Inc. (NASDAQ:TRIL)(TSX:TRIL) a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the company is scheduled to present an update on the company's programs and progress at several upcoming conferences.

Investor Conference:
	16th Annual Needham Healthcare Conference
	Presenter: Niclas Stiernholm, Ph.D., President & Chief Executive Officer
	Date and Time: April 5, 2017 at 4:40 p.m. ET
	Location: The Westin NY Grand Central Hotel, New York

Scientific Conferences:
	110th American Association for Cancer Research Annual Meeting 2017
	Presenter: Gloria Lin, Ph.D., Trillium Research Scientist
	Title: Intratumoral Delivery of TTI-621 (SIRPaFc), a CD47-Blocking Immunotherapeutic, Inhibits Tumor Growth and Prolongs Animal Survival in a Subcutaneous B cell Lymphoma Model
	Date and Time: April 3, 2017, 1:00 p.m. - 5:00 p.m. ET
	Location: Walter E. Washington Convention Center, Washington, D.C., Halls A-C, Poster Section 26
	Presenter: Emma Linderoth, Ph.D., Trillium Research Scientist
	Title: The Anti-Myeloma Activity of TTI-621 (SIRPαFc), a CD47-Blocking Immunotherapeutic, is Enhanced When Combined with a Proteasome Inhibitor
	Date and Time: April 3, 2017, 1:00 p.m. - 5:00 p.m. ET
	Location: Walter E. Washington Convention Center, Washington, D.C., Halls A-C, Poster Section 26

About Trillium Therapeutics